[Pathophysiology of sepsis and possible influence of statins].
| Autor: | Fraunberger P; Medizinisches Zentrallabor, Feldkirch, Österreich. pfraunberger@mzl.at, Drexel H, Walli AK |
|---|---|
| Jazyk: | němčina |
| Zdroj: | Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2010 Oct; Vol. 135 (43), pp. 2128-32. Date of Electronic Publication: 2010 Oct 19. |
| DOI: | 10.1055/s-0030-1267491 |
| Abstrakt: | Severe sepsis and septic shock are common complications in the intensive care unit and associated with high mortality. Early antimicrobial therapies together with organ-supportive measures are the major therapeutic approaches. However in the last decades immunomodulatory therapies have been investigated due to the notion of a compromised inflammatory response in septic patients. In addition to lowering circulating cholesterol, statins (HMG-CoA-reductase-inhibitors) have also been shown to possess pleiotropic anti-inflammatory potential. Recent studies indicate that these anti-inflammatory effects also modulate acute inflammatory response and therefore may play a protective role in septic patients. In this review, the pathophysiological background and first clinical trials of statins as a new adjuvant therapy in sepsis are summarized. (© Georg Thieme Verlag KG Stuttgart · New York.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|